Compare Match Group Inc (MTCH) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs TG Therapeutics Inc — how do they compare? Match Group Inc trades at $41.46 (market cap $9.51B), while TG Therapeutics Inc trades at $54.77 (market cap $8.36B). The key difference: Match Group Inc and TG Therapeutics Inc are close in size by market cap, and Match Group Inc pays a 1.93% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MTCH | TGTX | |
|---|---|---|
Market Cap | $9.51B | $8.36B |
Sector | Media | Health |
52-Week High | $42.44 | $59.06 |
52-Week Low | $28.90 | $26.94 |
Enterprise Value | $12.48B | $8.57B |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $41.15, down 1.7% today, near its consensus price target of $42.50. The stock shows a bullish technical signal with support at $41 and resistance at $42. Recent earnings beat expectations in Q2 2026, with Q3 2026 results pending. Revenue stability around $3.5B and a net income margin of 20.17% reflect solid profitability, though high debt levels pose a risk. Analysts are overwhelmingly positive with 53% buy ratings and no sell recommendations.
The outlook for MTCH is cautiously optimistic, driven by product innovation at Tinder and strong cash flow growth. Investment opportunities include potential upside to the $45 high price target and dividend payments. Risks include elevated long-term debt of $3.85B and competitive pressures in the dating app market. Investors should monitor Q3 2026 earnings for confirmation of growth trends.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
